The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.

EP. 1: An Introduction to DLBCL: Current Approaches and Challenges

September 15th 2021

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, explain the intricacies of the diffuse large B-cell lymphoma treatment landscape.

EP. 2: Treatment Methods: Transplant Eligibility in R/R DLBCL and CAR T Cell Therapy

September 15th 2021

The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients.

EP. 3: CD19 As a Targeted Agent in CAR T Cell Therapy for R/R DLBCL

September 22nd 2021

Drs Shadman and Hill discuss using CD19 as a targeted therapy option in CAR T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.

EP. 4: CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab

September 22nd 2021

Dr Mazyar Shadman and Dr Brian T. Hill focus on CD19 being targeted in monoclonal antibody therapy options for relapsed/refractory diffuse large B-cell lymphoma, specifically tafasitamab.

EP. 5: CD19-Targeted mAbs in R/R DLBCL Using Tafasitamab Continued

September 30th 2021

The discussion of tafasitamab as a monoclonal antibody therapy option for relapsed/refractory diffuse large B-cell lymphoma continues.

EP. 6: CD19-Targeted mAbs in RR DLBCL Using Loncastuximab Tesirine

September 30th 2021

The doctors switch their monoclonal antibody conversation’s focus to longcastuximab tesirine for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

EP. 7: Bispecific Antibody Therapy R/R DLBCL

October 6th 2021

Two experts examine bispecific antibody treatment use for relapsed/refractory diffuse large B-cell lymphoma.

EP. 8: The Future of DLBCL Treatment

October 6th 2021

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, consider potential treatment options for relapsed/refractory diffuse large B-cell lymphoma in the future.